T reatment of hepatitis C virus (HCV) infection has undergone a dramatic change with the new direct-acting antivirals (DAAs), by decreasing treatment duration and side effects associated with prior pegylated-interferon (PEG-IFN)-based treatments. 1, 2 In the current interferon-free era, the increased incidence of bacterial infections seems to have been overcome. However, we observed several cases of herpesvirus (HV) reactivation during or shortly after treatment with different combinations of DAAs.
Methods
A review was performed of 576 patients with chronic HCV infection treated with DAAs between November 2014 and November 2015 in 3 Spanish university hospitals. A historic control cohort of 236 sex-and age-matched HCVinfected patients was used, with a median follow-up period of 37 months. This control cohort encompassed 23 untreated patients (10%) and 213 patients (90%) treated with IFN-based regimens, including PEG-IFN þ ribavirin (RBV) and triple therapy using first-wave protease inhibitors. The cohort included 10 patients (4%) with liver transplantation (LT) (1 untreated, 9 treated).
Results
We identified 10 of 576 cases (2%) of HV reactivation during treatment in 2 populations: nonimmunocompromised and medically immunocompromised patients (LT) ( Table 1) . The clinical presentations were as follows: 7 of 10 cutaneous, 2 of 10 ocular, and 1 of 10 labialis. The median age was 67 years. Most patients had advanced liver fibrosis and 3 of the patient had undergone LT. HV reactivation was diagnosed at a median of 8 weeks after therapy initiation. Complications included postherpetic neuralgia (PHN) (2 of 10 patients), and herpetic kerato-uveitis (1 of 10 patients). The HCV regimens were as follows: sofosbuvir/ledipasvir AE RBV (7 of 10 patients), ombitasvir/paritaprevir/ritonavir þ dasabuvir AE RBV (2 of 10 patients), and sofosbuvir/ simeprevir þ RBV (1 of 10 patients).
Case 1
The first case was a 68-year-old man who was treatment experienced and who underwent LT in 2009 owing to decompensated cirrhosis and hepatocellular carcinoma (HCC). He was treated with sofosbuvir/ ledipasvir þ RBV (1200 mg/24 h) for 24 weeks. At week 20 he developed monometameric dorsal herpes zoster with severe pain (Figure 1) , which was treated with famciclovir (500 mg/8 h) for 7 days and analgesics. The patient developed PHN and needed ablation for pain control. Currently, he still has residual symptoms and has achieved sustained virologic response (SVR).
Case 2
The second case was a 75-year-old woman with HVCrelated cirrhosis and treatment experience. She underwent a LT in 2009 owing to cirrhosis and HCC. She received sofosbuvir/ledipasvir þ RBV (1000 mg/24 h) during 24 weeks. At week 10, she presented with monometameric right hemithorax herpes zoster and she was treated with famciclovir 500 mg/8 h and analgesics. The patient developed PHN and received gabapentin as treatment, recovering without sequelae, and also achieving SVR.
Case 3
The third case was a 57-year-old man who underwent a LT in 2013 owing to HCV-related cirrhosis and HCC. After HCV recurrence and a cryoglobulinemic vasculitis, he started treatment with sofosbuvir/ledipasvir þ RBV (800 mg/24 h). At week 8, he developed a monometameric herpes zoster treated with valacyclovir 1 g/8 h. Complete resolution was achieved. The patient completed 12 weeks post-HCV treatment with an undetectable RNA (SVR).
Case 4
The fourth case was a 59-year-old woman, HCVtreatment experienced with decompensated cirrhosis (medically controlled ascites), treated with sofosbuvir þ simeprevir þ RBV (1000 mg/24 h) during 12 weeks. At week 6, the patient was diagnosed with ocular herpes. She received oral acyclovir (800 mg/4 h) for 7 days without sequelae and completed HCV treatment, achieving SVR.
Case 5
The fifth case was a 70-year-old woman with chronic hepatitis C, and previous early discontinuation of PEG-IFN þ RBV. She received treatment with ombitasvir/paritaprevir/ritonavir þ dasabuvir during 12 weeks. At week 10, she developed severe herpes labialis, which completely resolved after oral acyclovir (800 mg/4 h) for 7 days. The patient completed HCV treatment, achieving SVR.
Case 6
The sixth case was a 73-year-old woman with compensated HCV-related cirrhosis who was a previous nonresponder. She began treatment with sofosbuvir/ ledipasvir during 24 weeks. At week 22 she presented with bilateral monometameric herpes zoster and was treated with famciclovir 500 mg/8 h for 7 days with no complications. Finally, the patient achieved SVR.
Case 7
The seventh case was a 79-year-old man with compensated HCV-related cirrhosis who was treatmentnaive. He was treated with sofosbuvir/ledipasvir during 12 weeks. After 8 weeks of treatment he developed herpes zoster that was treated with valacyclovir 1 g/8 h for 7 days. HCV treatment was completed, and he achieved SVR.
Case 8
The eighth case was a 58-year-old man who was a previous nonresponder, and was treated with sofosbuvir/ledipasvir þ RBV (1000 mg/24 h) during 24 weeks. At week 4, he developed herpes zoster treated with acyclovir (800 mg/4 h) for 7 days. He later developed a PHN that required treatment with pregabalin. The patient currently has an SVR.
Case 9
The ninth case was a 71-year-old woman with compensated HCV-related cirrhosis (esophageal varices on primary prophylaxis with propranolol), and who was treatment-naive. She began treatment with ombitasvir/ paritaprevir/ritonavir þ dasabuvir þ RBV (1000 mg/d).
At week 4 she was diagnosed with periorbital herpes and was started on acyclovir 800 mg/4 h during 7 days, with complete resolution of symptoms. Currently, the patient has undetectable HCV RNA at week 12 post-treatment, thus, SVR.
Case 10
The 10th case was a 67-year-old woman who was treatment experienced and is awaiting liver transplantation for HCV-related cirrhosis and HCC. The patient started treatment with sofosbuvir/ledipasvir þ RBV (600 mg/d). At week 4, she was diagnosed with severe ophthalmic herpes with associated kerato-uveitis and was treated with valacyclovir 1 g/8 h during 7 days. Currently, the patient has achieved SVR.
Discussion
In the interferon era, bacterial infections were relatively common in patients receiving treatment for HCV, especially when advanced liver disease was present.
1,2
With new interferon-free regimens, infectious complications do not appear to be a problem in this setting.
The herpesvirus family is known for its ability to establish life-long infection. 3 Most adults are infected with herpes virus-1, varicella-zoster virus (VZV), Epstein-Barr virus, and probably herpes virus-6 and herpes virus-7. 4 Herpes zoster (HZ) is the result of reactivation of a previous VZV infection, remaining latent in cranial nerves and dorsal root ganglia and manifesting in periods when there is a direct or indirect down-regulation of the immune system. 3, 5, 6 However, balance between latency and reactivation of VZV seems to be a complex process in which a precise understanding of the activated pathways by clinical factors is lacking. 3 Several studies have shown that VZV reactivation, most commonly as cutaneous herpes zoster, can be observed in transplanted patients receiving immunosuppressive treatment. Those patients receiving a more intensive immunosuppression (typically heart or lung recipients) are at higher risk, particularly with age older than 60 years. [5] [6] [7] Cases 1, 2, and 3 were LT patients, and 2 of these patients were older than age 65, and therefore they would share some of the earlier-mentioned risk factors (Table 1) . Nevertheless, all of the reactivations that occurred in our patients happened during HCV treatment.
Regarding the other 7 immunocompetent patients, a diminished lymphocyte count and advanced age in cases 4, 5, and 9 could be considered as predisposing conditions (Table 1 and Supplementary Table 1 ). We could not find any other typical risk factor for HV reactivation, such as psychological or physical stress, concurrent infection, or significant anemia. Disregarding immune impairment previously described in cirrhotic patients, specific immune disturbances also have been described in chronic infection with HCV. However, treatment with DAAs theoretically would restore these disturbances related to an exhausted immune system, especially regarding cellular immunity. [8] [9] [10] Thus, the mechanism of these reactivations could even seem paradoxic.
Two different arguments could be advocated to enlighten our findings. First, 3 cases of hepatitis B virus (HBV) reactivation have been reported recently in patients treated with simeprevir and sofosbuvir. 11, 12 The authors of the case reports on HBV reactivation proposed that viral interference on HBV replication caused by HCV would be disrupted by treatment with DAAs. Therefore, HBV would experience a reactivation after HCV clearance, boosted by PEG-IFN absence. These reports justified a recent review statement on HBV reactivation by the European Medicines Agency. 13 Second, it is tempting to trace some parallelisms with immune reconstitution inflammatory syndrome (IRIS), which can be seen in some human immunodeficiency virus-infected patients after highly active antiretroviral therapy. This syndrome implies a pathologic inflammatory response to previously acquired conditions in the setting of an improved immune response, mucocutaneous HZ being one of them.
14 IRIS can happen even several months after initiation of highly active antiretroviral therapy. Similarly, we observed 2 extra cases of HZ reactivation at 1 and 3 weeks after the end of treatment (data not shown). Bearing in mind the earlier-mentioned immune implications of HCV chronic infection and treatment with DAA, it is interesting that cellular immunity has been related specifically to VZV reactivation in patients with IRIS. 8, 15 On the other hand, immune changes after quick HCV clearance may be complex, including a down-regulation of interferon-stimulated genes, which are key elements of antiviral defense. 16 In addition, an important report was published very recently on the possible risk of hepatocellular carcinoma reactivation after DAA treatment. 17 One of the explanations could be a decrease in immune surveillance as a result of a sudden and early viral clearance in the context of IFN-free regimens. In sum, treatment with a DAA alone might lead to a transitory change of immune status, which would favor HV reactivation in some patients.
The incidence of HV reactivation was low in our cohort (1.74% per person-year; 95% confidence interval, 0.84%-3.17%). Nevertheless, we compared this series with a control cohort of HCV-infected patients either untreated or treated with IFN-based regimens, and no patient from this cohort showed HV reactivation.
Even when a causal relationship is not definitive, based on the temporal association and recent experience we conclude that the incidence of HV reactivation may be increased among patients on IFN-free regimens. Therefore, we advise a high grade of clinical suspicion to prescribe early treatment. HV status also may be checked when other risk factors are present (LT or advanced age) and VZV vaccine may be useful for non-LT patients before HCV treatment. 18 More research is necessary in this new field because unexpected events might be arising in patients treated with DAA. 
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